Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2a Add-on in Suppressed Chronic Hepatitis B
NCT02982837Phase 4Unknown
- Sponsor
- King Abdullah International Medical Research Center
- Start
- Mar 2015
- Primary completion
- Mar 2019
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a in Chronic Hepatitis B (CHB) (2 arms), sponsored by King Abdullah International Medical Research Center. Primary endpoint: Hepatitis B surface antigen loss at 48 weeks. Status: unknown.
02
Drugs
peginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02982837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982837.